Nasdaq
$88.78▲ 0.89%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $7.04BShares out 79.3M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
3- 9.21After-hours26.09.22 05:21F-6EFOffering#●●●#●●●
Abivax S.A.
Abivax S.A. filed a registration statement (Form F-6) on September 21, 2026, for 100 million American Depositary Shares (ADSs). This filing formalizes the issuance and management procedures for ADSs under existing deposit agreements and includes the issuance of 403,347 ordinary shares to royalty certificate holders in exchange for their certificates.…more
$88.78+0.89%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 9.21After-hours26.09.22 05:126-KKey event
Abivax S.A.
Abivax reported its financial results for the first half of 2026, confirming a cash runway extending into Q4 2029 following a public offering in July. The company also completed the buy-back of all outstanding royalty certificates to strengthen its financial position and appointed new leadership to prepare for the potential commercialization of obefazimod.…more
$88.78+0.89%vs prev closeView filingShare - 8.13Regular26.08.13 23:55SCHEDULE 13G/AOwnership
Abivax S.A.
Invus Public Equities, L.P. and seven other entities, along with Raymond Debbane, entered into a joint filing agreement on August 13, 2026, regarding their ownership of Abivax S.A. securities. This agreement formalizes the joint reporting and management of their stake in the company under Schedule 13G.…more
$88.78+0.89%vs prev closeView filingShare
2 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 9.30After-hours26.10.01 05:05#●●●#●●●
Abivax to Present Obefazimod Clinical Data at UEG Week 2026
Abivax will present Phase 3 and Phase 2 clinical data for its ulcerative colitis drug candidate, obefazimod, at the upcoming United European Gastroenterology (UEG) Week. As these presentations focus on reinforcing existing clinical findings, the impact on the stock price is expected to be neutral.…more
$88.78+0.89%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 9.21After-hours26.09.22 05:40
●●●●●●●● ●●●●● ●●●●●●
Abivax reported quarterly revenue that beat analyst estimates, but its earnings per share fell significantly short of expectations. The company saw a year-over-year decline in sales and an increase in net losses, highlighting ongoing profitability challenges.…more
$88.78+0.89%vs prev closeShareBenzinga - 9.21After-hours26.09.22 05:05
●●●●●●●● ●●●●● ●●●●●●
Abivax announced its first-half 2026 financial results alongside leadership changes to prepare for the potential commercialization of its lead drug candidate, obefazimod. While the company secured a cash runway through Q4 2029 via a public offering, it reported increased operating losses due to higher R&D expenditures.…more
$88.78+0.89%vs prev close
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report